Rheumatoid Arthritis (RA) presents a clinical challenge, especially when dealing with Refractory RA, because standard therapy fails to improve the patient’s condition. A new finding achieved through Ultrasound-Guided Synovial Biopsy (UGSTB), led by Dr. Alessandro Giollo at the University of Padua (Italy), may radically change the approach to managing treatment-resistant RA.
The research aimed to clarify why some forms of RA resist advanced therapy with biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). Histopathological analysis of synovial tissue, performed in patients with refractory RA, revealed two distinct biological pathotypes that underlie the persistence of the disease:
Inflammatory Refractory RA (PIRRA)
This group confirms an ongoing inflammatory process. Biopsy studies showed marked infiltration of immune cells, especially lymphoid and myeloid cells. Patients exhibited high levels of inflammatory markers such as C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR), which correlated with the clinical picture (swollen joints).
Therapeutic Approach: In PIRRA, inflammation remains the leading mechanism of the disease, requiring intensive immunomodulatory therapy. In this specific case, Janus kinase inhibitors or Interleukin-6 blockers may be the most effective.
Non-Inflammatory Refractory RA (NIRRA)
This group is entirely different in terms of histological features; the joint tissue shows a pauci-immune fibroid pathotype (minimal inflammatory infiltration). Despite this, patients experienced pain, rigidity, and functional limitation that was equal to or even exceeded the severity of the inflammatory pathotype (PIRRA). Opioid use, as well as comorbidities like fibromyalgia and depression, were common in this group.
Therapeutic Approach: These findings suggest that the cause of persistent RA symptoms may not be inflammation, but rather altered pain modulation in the nervous system or central sensitization. Accordingly, aggressive immunosuppressive therapy may be ineffective and potentially harmful for these patients. Priority should be given to multimodal pain management, physical rehabilitation, cognitive-behavioral approaches, and non-opioid analgesics.
The study showed that widely used disease activity scores and reliance on joint ultrasound alone cannot differentiate these two groups. For instance, the ultrasound Power Doppler signal indicated inflammation in PIRRA, but it could not distinguish NIRRA from non-refractory RA, which created a risk of misclassification.
The data justifies the widespread use of UGSTB in clinical practice. This will allow doctors to obtain detailed information directly from the joint and precisely tailor therapy to the patient’s biological pathotype. This approach will prevent unnecessary immunosuppression in patients who do not respond to it, reducing side effects and healthcare costs.
Source: Annals of Rheumatic Diseases
